Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
BPMC Analyst Ratings
Hold
4 Buy
16 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BPMC Stock 12 Month Forecast
Average Price Target
$129.63
▲(1.39%Upside)
| Highest Price Target$143.00 | Average Price Target$129.63 | Lowest Price Target$105.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$128
Hold
0.12%
Upside
Reiterated
06/03/25
Blueprint Medicines' overall score is primarily impacted by its strong financial growth potential and positive earnings call sentiment. However, profitability challenges and an overvalued stock, as indicated by the P/E ratio, weigh heavily on the score. Technical indicators show a bullish trend, but potential overbought conditions warrant caution. The corporate merger event, while positive, is excluded from weighted scoring but is a significant strategic advantage.
UBS
$88→$129
Hold
0.90%
Upside
Reiterated
06/05/25
Morgan Stanley
$102→$129
Hold
0.90%
Upside
Reiterated
06/05/25
Citi
$83→$129
Hold
0.90%
Upside
Upgraded
06/04/25
Guggenheim
$132
Hold
3.25%
Upside
Downgraded
06/03/25
Robert W. Baird
$135→$131
Buy
2.46%
Upside
Reiterated
06/03/25
TD Cowen
$130
Hold
1.68%
Upside
Downgraded
06/03/25
Stephens
$150→$135
Hold
5.59%
Upside
Downgraded
06/03/25
Leerink Partners
$93→$129
Hold
0.90%
Upside
Reiterated
06/03/25
Barclays
$105
Hold
-17.87%
Downside
Reiterated
06/03/25
Citizens JMP
―
Hold
―
Downgraded
06/03/25
Wells Fargo
$143
Buy
11.85%
Upside
Reiterated
06/02/25
Wedbush
$128→$129
Hold
0.90%
Upside
Downgraded
06/02/25
Wolfe Research
―
Hold
―
Downgraded
06/02/25
Needham
―
Hold
―
Downgraded
06/02/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$128
Hold
0.12%
Upside
Reiterated
06/03/25
Blueprint Medicines' overall score is primarily impacted by its strong financial growth potential and positive earnings call sentiment. However, profitability challenges and an overvalued stock, as indicated by the P/E ratio, weigh heavily on the score. Technical indicators show a bullish trend, but potential overbought conditions warrant caution. The corporate merger event, while positive, is excluded from weighted scoring but is a significant strategic advantage.
UBS
$88→$129
Hold
0.90%
Upside
Reiterated
06/05/25
Morgan Stanley
$102→$129
Hold
0.90%
Upside
Reiterated
06/05/25
Citi
$83→$129
Hold
0.90%
Upside
Upgraded
06/04/25
Guggenheim
$132
Hold
3.25%
Upside
Downgraded
06/03/25
Robert W. Baird
$135→$131
Buy
2.46%
Upside
Reiterated
06/03/25
TD Cowen
$130
Hold
1.68%
Upside
Downgraded
06/03/25
Stephens
$150→$135
Hold
5.59%
Upside
Downgraded
06/03/25
Leerink Partners
$93→$129
Hold
0.90%
Upside
Reiterated
06/03/25
Barclays
$105
Hold
-17.87%
Downside
Reiterated
06/03/25
Citizens JMP
―
Hold
―
Downgraded
06/03/25
Wells Fargo
$143
Buy
11.85%
Upside
Reiterated
06/02/25
Wedbush
$128→$129
Hold
0.90%
Upside
Downgraded
06/02/25
Wolfe Research
―
Hold
―
Downgraded
06/02/25
Needham
―
Hold
―
Downgraded
06/02/25
Best Analysts Covering Blueprint Medicines
1 Month
xxx
Success Rate
10/17 ratings generated profit
Average Return
+2.54%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.82% of your transactions generating a profit, with an average return of +2.54% per trade.
3 Months
xxx
Success Rate
11/17 ratings generated profit
Average Return
+10.13%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +10.13% per trade.
1 Year
Success Rate
14/17 ratings generated profit
Average Return
+26.78%
reiterated a buy rating 7 days ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +26.78% per trade.
2 Years
xxx
Success Rate
23/23 ratings generated profit
Average Return
+60.44%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +60.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BPMC Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
4
6
8
5
3
Buy
17
20
16
15
13
Hold
11
13
9
8
21
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
39
33
28
37
Each month's total comprises the sum of three months' worth of ratings.
BPMC Financial Forecast
BPMC Stock Forecast FAQ
What is BPMC’s average 12-month price target, according to analysts?
Based on analyst ratings, Blueprint Medicines’s 12-month average price target is 129.63.
What is BPMC’s upside potential, based on the analysts’ average price target?
Blueprint Medicines has 1.39% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BPMC a Buy, Sell or Hold?
Blueprint Medicines has a consensus rating of Hold which is based on 4 buy ratings, 16 hold ratings and 0 sell ratings.
What is Blueprint Medicines’s price target?
The average price target for Blueprint Medicines is 129.63. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $143.00 ,the lowest forecast is $105.00. The average price target represents 1.39% Increase from the current price of $127.85.
The highest analyst price target is $143.00 ,the lowest forecast is $105.00. The average price target represents 1.39% Increase from the current price of $127.85.
What do analysts say about Blueprint Medicines?
Blueprint Medicines’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of BPMC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.